How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

887 results for

Rivastigmine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Response to Rivastigmine Transdermal Patch or Memantine plus Rivastigmine Patch is affected by Apolipoprotein E Genotype in Alzheimer Patients. (Abstract)

Response to Rivastigmine Transdermal Patch or Memantine plus Rivastigmine Patch is affected by Apolipoprotein E Genotype in Alzheimer Patients. The apolipoprotein E (APOE) genotype in response to pharmacological treatments in patients with Alzheimer's disease (AD) remains a matter of controversy. This analysis investigated the effect of the APOE genotype on the clinical response to rivastigmine transdermal patch monotherapy or memantine plus rivastigmine patch in patients with mild to moderate (...) AD.Two hundred and six (n = 206) patients with probable AD and Mini-Mental State Examination (MMSE) scores of 10-20 were randomized to rivastigmine patch monotherapy or memantine plus rivastigmine patch for 24 weeks. Of the 206 patients with probable AD, 146 patients who consented to genetic testing for APOE were included and assessed for this subgroup study.There were no significant differences on MMSE, NPI, ADAS-cog, ADCS-ADL, CDR-SB, NPI and FAB between rivastigmine patch monotherapy and memantine

2012 Dementia and Geriatric Cognitive Disorders Controlled trial quality: uncertain

102. Rivastigmine in the treatment of postoperative delirium: a pilot clinical trial. (Abstract)

Rivastigmine in the treatment of postoperative delirium: a pilot clinical trial. 22886871 2012 12 03 2015 11 19 1099-1166 27 9 2012 Sep International journal of geriatric psychiatry Int J Geriatr Psychiatry Rivastigmine in the treatment of postoperative delirium: a pilot clinical trial. 986-8 10.1002/gps.2801 Zaslavsky Alexander A Haile Michael M Kline Rick R Iospa Alla A Frempong-Boadu Anthony A Bekker Alex A eng Letter Randomized Controlled Trial England Int J Geriatr Psychiatry 8710629 0885 (...) -6230 0 Neuroprotective Agents 0 Phenylcarbamates PKI06M3IW0 Rivastigmine IM Aged Aged, 80 and over Analysis of Variance Brief Psychiatric Rating Scale Delirium diagnosis drug therapy Double-Blind Method Female Humans Male Neuroprotective Agents therapeutic use Phenylcarbamates therapeutic use Pilot Projects Postoperative Complications diagnosis drug therapy Rivastigmine 2012 8 14 6 0 2012 8 14 6 0 2012 12 10 6 0 ppublish 22886871 10.1002/gps.2801

2012 International Journal of Geriatric Psychiatry Controlled trial quality: uncertain

103. Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia

Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01585272 Recruitment Status : Completed

2012 Clinical Trials

104. Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved (...) Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our

2012 Clinical Trials

105. Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20) Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2012 Clinical Trials

106. Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine

Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search (...) for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been

2012 Clinical Trials

107. Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI

Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Rivastigmine (...) . This study will evaluate the effects of the cholinesterase inhibitor rivastigmine transdermal patch in Veterans with TBI and posttraumatic memory problems. Results will provide much needed data that will help treat Veterans with TBI. Condition or disease Intervention/treatment Phase Traumatic Brain Injury Cognitive Impairment Drug: Rivastigmine Transdermal Patch Phase 3 Detailed Description: Traumatic brain injury (TBI) represents one of the most significant health risks related to military duty; rapidly

2012 Clinical Trials

108. Efficacy of rivastigmine in comparison to ginkgo for treating Alzheimer's dementia. (Abstract)

Efficacy of rivastigmine in comparison to ginkgo for treating Alzheimer's dementia. To assess the efficacy of the Ginkgo biloba in patients with dementia of the Alzheimer type in slowing down the disease's degenerative progression and the patients' cognitive impairment compared with rivastigmine.Total 56 patients aged 50-75 years, suffering from dementia, were allocated into one of the two treatments: group 1) Ginkgo biloba (120 mg daily dose); group 2) rivastigmine (4.5 mg daily dose) in a 24 (...) -week randomized double blind study. The degree of severity of dementia was assessed by the Seven Minute test and the Mini-Mental State Examination.Our results confirm the clinical efficacy of rivastigmine in the dementia of the Alzheimer type, comparing to Ginkgo biloba. There are few published trials that have directly compared a cholinesterase inhibitor with Ginkgo for dementia. This study directly compares a cholinesterase inhibitor with Ginkgo biloba for dementia of the Alzheimer type.Our study

2012 JPMA. The Journal of the Pakistan Medical Association

109. Rivastigmine reduces "Likely to use methamphetamine" in methamphetamine-dependent volunteers. Full Text available with Trip Pro

Rivastigmine reduces "Likely to use methamphetamine" in methamphetamine-dependent volunteers. We previously reported that treatment with the cholinesterase inhibitor rivastigmine (3mg, PO for 5days) significantly attenuated "Desire for METH". Given that higher dosages of rivastigmine produce greater increases in synaptic ACh, we predicted that 6mg should have more pronounced effects on craving and other subjective measures. In the current study, we sought to characterize the effects of short (...) -term exposure to rivastigmine (0, 3 or 6mg) on the subjective and reinforcing effects produced by administration of methamphetamine (METH) in non-treatment-seeking, METH-dependent volunteers. This was a double-blind, placebo-controlled, crossover study. Participants received METH on day 1, and were then randomized to placebo or rivastigmine on day 2 in the morning and treatment continued through day 8. METH dosing was repeated on day 6. The data indicate that METH (15 and 30mg), but not saline

2012 Progress in neuro-psychopharmacology & biological psychiatry Controlled trial quality: uncertain

110. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. (Abstract)

Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. We report on a double-blind, crossover pilot trial for the treatment of rapid eye movement behavior disorder (RBD) in 12 patients with Parkinson's disease in whom conventional therapy failed.We employed a patch of the cholinesterase inhibitor rivastigmine at a dose of 4.6 mg/24 hours for 3 weeks compared with placebo to reduce the frequency of RBD episodes. The number of RBD episodes was monitored

2012 Movement disorders : official journal of the Movement Disorder Society Controlled trial quality: uncertain

111. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. (Abstract)

Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. Electroconvulsive therapy (ECT) is an effective strategy in some treatment-resistant patients with schizophrenia. However, ECT is associated with cognitive adverse effects, most notably, memory loss. This study examined the effects of rivastigmine, a selective central nervous system acetylcholinesterase inhibitor, with benefits on cognition in Alzheimer disease (...) , on memory performance in patients with schizophrenia treated with ECT. Thirty inpatients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision schizophrenia treated with ECT were coadministered rivastigmine (3-4.5 mg/d) or placebo in a prospective, randomized, double-blind, placebo-controlled trial (maximum period of 4 weeks). Over the ECT course, scores on the cognitive subscale of the Alzheimer's Disease Assessment in subjects receiving placebo showed no significant

2012 Clinical neuropharmacology Controlled trial quality: uncertain

112. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease. Full Text available with Trip Pro

Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease. Determine whether patients with Alzheimer's disease demonstrating functional and cognitive decline, following 24-48 weeks of open-label treatment with 9.5 mg/24 h (10 cm(2)) rivastigmine patch, benefit from a dose increase in a double-blind (DB) comparative trial of two patch doses.Patients meeting prespecified decline criteria were (...) and ADAS-cog scores favoured the 13.3 mg/24 h patch. The 13.3 mg/24 h patch was statistically superior to the 9.5 mg/24 h patch on the ADCS-IADL scale from week 16 (p = 0.025) onwards including week 48 (p = 0.002), and ADAS-cog at week 24 (p = 0.027), but not at week 48 (p = 0.227). No unexpected safety concerns were observed.The 13.3 mg/24 h rivastigmine patch significantly reduced deterioration in IADL, compared with the 9.5 mg/24 h patch, and was well tolerated.Copyright © 2012 S. Karger AG, Basel.

2012 Dementia and Geriatric Cognitive Disorders Controlled trial quality: uncertain

113. Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial. Full Text available with Trip Pro

Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial. Delirium is frequently diagnosed in critically ill patients and is associated with adverse outcome. Impaired cholinergic neurotransmission seems to have an important role in the development of delirium. We aimed to establish the effect of the cholinesterase inhibitor rivastigmine on the duration (...) of delirium in critically ill patients.Patients (aged ≥18 years) who were diagnosed with delirium were enrolled from six intensive care units in the Netherlands, and treated between November, 2008, and January, 2010. Patients were randomised (1:1 ratio) to receive an increasing dose of rivastigmine or placebo, starting at 0·75 mL (1·5 mg rivastigmine) twice daily and increasing in increments to 3 mL (6 mg rivastigmine) twice daily from day 10 onwards, as an adjunct to usual care based on haloperidol

2010 Lancet Controlled trial quality: predicted high

114. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis Full Text available with Trip Pro

, and maximising the patient’s independence ( ). Cholinesterase inhibitors are medicines recommended as options for managing mild to moderate dementia due to Alzheimer's disease in several clinical guidelines ( ; ). Alzheimer's disease is the most common cause of dementia and is found in approximately 70% of autopsies of people with dementia ( ). The three cholinesterase inhibitors currently marketed for the treatment of Alzheimer's disease are donepezil, rivastigmine and galantamine. Cholinesterase inhibitors (...) are taken orally once or twice a day, or, in the case of rivastigmine, can be applied transdermally. Well‐designed, placebo‐controlled trials involving large numbers of participants have reported modest cognitive benefit from cholinesterase inhibitors in mild to moderate dementia due to Alzheimer's disease ( ). However, a number of harms due to the use of cholinesterase inhibitor treatment have also been reported. A previous Cochrane Review reported that there is evidence of more adverse events overall

2019 Cochrane Database of Systematic Reviews

115. Dementia: assessment, management and support for people living with dementia and their carers

dementia subtypes Managing medicines for all dementia subtypes 1.5.1 For guidance on managing medicines (including covert administration), see the NICE guidelines on managing medicines for adults receiving social care in the community and managing medicines in care homes. Pharmacological management of Alzheimer's disease Pharmacological management of Alzheimer's disease 1.5.2 The three acetylcholinesterase (AChE) inhibitors donepezil, galantamine and rivastigmine as monotherapies are recommended (...) as options for managing mild to moderate Alzheimer's disease under all of the conditions specified in 1.5.5 and 1.5.6. This recommendation is from NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. 1.5.3 Memantine monotherapy is recommended as an option for managing Alzheimer's disease for people with: moderate Alzheimer's disease who are intolerant of or have a contraindication to AChE inhibitors or or Dementia: assessment

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

117. Pharmacological interventions for the treatment of delirium in critically ill adults. Full Text available with Trip Pro

; all dexmedetomidine), statins (n = 2), opioids (n = 1; morphine), serotonin antagonists (n = 1; ondansetron), and cholinesterase (CHE) inhibitors (n = 1; rivastigmine). Only one of these trials consistently used non-pharmacological interventions that are known to improve patient outcomes in both intervention and control groups.Eleven studies (n = 1153 participants) contributed to analysis of the primary outcome. Results of the NMA showed that the intervention with the smallest ratio of means (RoM (...) antipsychotics (RoM 0.96, 95% CrI 0.64 to1.36; SUCRA 0.468; high-quality evidence).The NMAs of multiple secondary outcomes revealed that only the alpha2 agonist dexmedetomidine was associated with a shorter duration of mechanical ventilation (RoM 0.55, 95% CrI 0.34 to 0.89; moderate-quality evidence), and the CHE inhibitor rivastigmine was associated with a longer ICU stay (RoM 2.19, 95% CrI 1.47 to 3.27; moderate-quality evidence). Adverse events often were not reported in these trials or, when reported

2019 Cochrane

118. Clinical practice guidelines for pain, agitation, delirium, sedation and mobilisation in the intensive care unit: A Rapid Review

. There is no published evidence that treatment with haloperidol reduces the duration of delirium in adult ICU patients. No evidence ii. Atypical antipsychotics may reduce the duration of delirium in adult ICU patients. Low iii. We do not recommend administering rivastigmine to reduce the duration of delirium in ICU patients. Moderate iv. We do not suggest using antipsychotics in patients at significant risk for torsades de pointes (i.e., patients with baseline prolongation of QTc interval, patients receiving

2019 Monash Health Evidence Reviews

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>